Background: Biologic therapies such as dupilumab and tralokinumab have highly impacted on the management of moderate-to-severe atopic dermatitis (AD). However, recent clinical observations reported paradoxical adverse events (AEs), including psoriasis ...
Nettis, Eustachio +52 more
core +1 more source
Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors
: Background: Tralokinumab has been recently approved for the management of moderate-to-severe atopic dermatitis (AD). Despite its effectiveness and safety have been widely reported, there are no studies investigating factors that may affect clinical ...
Potestio, Luca +2 more
core +1 more source
Tralokinumab in the Era of Disruption in Atopic Dermatitis
EMJ DermatologyWhile for some individuals with atopic dermatitis (AD), the disease can be controlled with topical treatments, those with moderate-to-severe AD often require systemic therapy for long-term disease control. Systemic treatments for AD include conventional systemic agents, small molecule inhibitors, and biologics, each with its own risks and benefits. For
openaire +1 more source
Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis. [PDF]
Clin Transl AllergyAlmaci M, Globig P, Redhu D, Worm M.
europepmc +1 more source
Biological treatment in atopic dermatitis-Lessons from the BioDay registry. [PDF]
J Eur Acad Dermatol VenereolZysk W, Trzeciak M.
europepmc +1 more source
Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis". [PDF]
Dermatol Ther (Heidelb)Rand K +8 more
europepmc +1 more source
Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology. [PDF]
Dermatol Ther (Heidelb)Augustin M, Hong HC, Torres T, Issa NT.
europepmc +1 more source
Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis. [PDF]
Intractable Rare Dis ResTanaka H, Ishii T.
europepmc +1 more source
A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'". [PDF]
Dermatol Ther (Heidelb)Augustin M +6 more
europepmc +1 more source
Use of Tralokinumab in a Hairdresser With Severe Chronic Hand Eczema and Occupational Allergic Contact Dermatitis. [PDF]
Contact DermatitisPortero-Campillo G +3 more
europepmc +1 more source